James Feinstein, MD

Website: http://www.ncbi.nlm.nih.gov/sites/myncbi/james.feinstein.1/bibliography/40361076/public/?sort=date&direction=descending

For Patients:
Pediatric complex chronic conditions, severe neurological impairment, pediatric pharmacoepidemiology (polypharmacy, drug-drug interactions, adverse drug events), medication safety, epidermolysis bullosa

For Referring Providers:
I am an Associate Professor in the Department of Pediatrics at the University of Colorado Anschutz Medical Campus and a Principal Investigator at ACCORDS (Adult and Child Consortium for Health Outcomes Research and Delivery Science). I practice as an Attending Primary Care Physician in the Children’s Hospital Colorado Special Care Clinic, a medical home for >5600 children with special healthcare needs, and I am Pediatric Director of a nationally recognized Epidermolysis Bullosa Multidisciplinary Program for children with genetic skin blistering disorders. As a fellowship-trained health services researcher with over 15 years of experience, I have successfully led multiple epidemiological and health services research studies focused on children with medical complexity, neurologic impairment, and pediatric polypharmacy. I have co-authored 2 widely used classification systems to identify (1) children with complex chronic conditions (CCCs) and (2) children with severe neurological impairment (SNI). I have also developed a system to measure parent-reported outcomes of symptoms (PRO-Sx) for children with SNI. My long-term research goal is to improve medication safety and health outcomes for children with medical complexity, with a focus on implementing and evaluating patient-centric strategies to optimize the management of pediatric polypharmacy. To this end, I am currently the PI for a Eunice Kennedy Shriver National Institute of Child Health and Human Development K23 Patient-Centered Career Development award to study the measurement of parent-reported symptoms in children exposed to polypharmacy. I am also Chair of the Colorado Medicaid Pharmacy and Therapeutics Committee, Co-Chair of the Children’s Hospital Association Pharmacoepidemiology & Drug Safety Workgroup, and Member of the NIH’s Best Pharmaceuticals for Children Act (BPCA) Pharmacoepidemiology Workgroup.